Project Description

De-Risking Early, Early Stage Drug Development

Date & Time:

January 19, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Every day in labs around the world MD/PhDs are hard at work searching for solutions to the most urgent medical problems – and BioMotiv is searching those labs for transformational discoveries that can become breakthrough medicines.
BioMotiv isn’t a venture fund or drug development company. Founded by the Harrington Project for Discovery and Development, BioMotiv is an incubator/accelerator that uses all the considerable resources at its disposal to move promising breakthrough drugs and therapies from academia to commercialization as quickly as possible.
BioMotiv’s validate and accelerate, syndicate, and build-to-buy approach offers significant benefits:
  • They work with discoveries that can be translated to medicines in a timely and cost-effective manner
  • Currently have 7 portfolio companies in various stages of development
  • Provide development skills, lab resources, and other assets necessary for the success of its portfolio companies
  • Continually in touch with large pharma companies to share progress and get input on their portfolio companies
Family Offices are encouraged to join our webinar January 19th to hear from BioMotiv CEO, Satish Jindal, PhD, and learn more about how their approach to innovation accelerates breakthrough discoveries into medicine.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.